QualityStocks would like to highlight China Medical Technologies Inc. (NASDAQ: CMED). The Company is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs.
In the company’s news yesterday,
China Medical Technologies announced its partnership with Leica Biosystems, a division of Leica Microsystems, a world leader in microscopes and scientific instruments.
Collaboratively, the companies will co-develop and market automated FISH kits to be used on the Leica BOND system, an automated advanced staining platform. CMED will market the automated FISH kits in China, while Leica has the option to sell the automated FISH kits in the rest of the world.
The FISH solutions are designed for tissue sample tests on HER-2, EGFR and TOP2A, genes in connection with the targeted cancer therapy drugs for breast cancer, lung cancer and stomach cancer patients. By creating an automated system of these FISH tests on the Leica BOND system, pathology laboratories and independent service laboratories can run these diagnostic tests more efficiently and with higher and more consistent quality.
The partnership reflects a key achievement for CMED, extending its global reach.
“These collaborations with Leica mark a significant milestone for us,” Xiaodong Wu, chairman and CEO of CMED stated in the press release. “We believe that FISH applications will be more widely used in various clinical applications on automated basis in the future. By partnering with Leica, one of the leading global players in anatomic pathology, we can provide more efficient and higher quality FISH diagnostic solutions to the end users not only in China, but also in the global markets through Leica’s extensive global network.”
The deal is expected to not only benefit both companies, but their customers as well.
“CMED is the market leader for FISH based diagnostics in China and has played a key role in the rapid development in the use of FISH in China, especially for tissue based companion diagnostic testing. This partnership will help Leica and CMED to offer customers in China a broad test menu of high quality FISH tests automated on the Leica BOND system,” commented Arnd Kaldowski, president of Leica Biosystems.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
